About GenomeDx Biosciences
GenomeDx Biosciences is a company based in San Diego (United States) founded in 2008.. GenomeDx Biosciences has raised $69.75 million across 14 funding rounds from investors including Merck Global Health Innovation Fund, CRG and Calibrium. The company has 159 employees as of December 31, 2022. GenomeDx Biosciences operates in a competitive market with competitors including Inflammatix, MDxHealth, Agendia, PathogenDX and Opko Health, among others.
- Headquarter San Diego, United States
- Employees 159 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genome Dx Biosciences Corp
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$69.75 M (USD)
in 14 rounds
-
Latest Funding Round
$7.96 M (USD), Series C
May 15, 2020
-
Investors
Merck Global Health Innovation Fund
& 5 more
-
Employee Count
159
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of GenomeDx Biosciences
GenomeDx Biosciences has successfully raised a total of $69.75M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $7.96 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Series C — $8.0M
-
First Round
First Round
(01 Jun 2009)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Debt – Conventional - GenomeDx Biosciences | Valuation |
investors |
|
| May, 2020 | Amount | Series C - GenomeDx Biosciences | Valuation |
investors |
|
| Apr, 2019 | Amount | Series C - GenomeDx Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GenomeDx Biosciences
GenomeDx Biosciences has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck Global Health Innovation Fund, CRG and Calibrium. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital is focused on the life science sector.
|
Founded Year | Domain | Location | |
|
CRG is recognized as a premier healthcare investment partner.
|
Founded Year | Domain | Location | |
|
Investments are made by CD-Venture in early-stage life sciences startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GenomeDx Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - GenomeDx Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genomedx Biosciences Comparisons
Competitors of GenomeDx Biosciences
GenomeDx Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, MDxHealth, Agendia, PathogenDX and Opko Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of diagnostic solutions for systemic infections
|
|
| domain | founded_year | HQ Location |
Epigenetic tests for personalized cancer assessment and treatment.
|
|
| domain | founded_year | HQ Location |
Genomic diagnostic products for cancer treatment are provided.
|
|
| domain | founded_year | HQ Location |
Provider of DNA-based pathogen testing kits
|
|
| domain | founded_year | HQ Location |
Molecular diagnostic products for prostate cancer assessment are provided.
|
|
| domain | founded_year | HQ Location |
Provides telomere length analysis technology for diagnosis
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genomedx Biosciences
Frequently Asked Questions about GenomeDx Biosciences
When was GenomeDx Biosciences founded?
GenomeDx Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is GenomeDx Biosciences located?
GenomeDx Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is GenomeDx Biosciences a funded company?
GenomeDx Biosciences is a funded company, having raised a total of $69.75M across 14 funding rounds to date. The company's 1st funding round was a Series C of $12.96M, raised on Jun 01, 2009.
How many employees does GenomeDx Biosciences have?
As of Dec 31, 2022, the latest employee count at GenomeDx Biosciences is 159.
What does GenomeDx Biosciences do?
GenomeDx Biosciences was founded in 2008 and is headquartered in San Diego, United States. Genomic tests for urologic cancers are developed and commercialized within the biotechnology sector. The proprietary Decipher GRID platform serves as a clinically annotated genomic expression database focused on urological cancers. The flagship product assesses metastasis risk in prostate cancer following surgery by evaluating expression levels of 22 biomarkers.
Who are the top competitors of GenomeDx Biosciences?
GenomeDx Biosciences's top competitors include Inflammatix, PathogenDX and Agendia.
Who are GenomeDx Biosciences's investors?
GenomeDx Biosciences has 6 investors. Key investors include Merck Global Health Innovation Fund, CRG, Calibrium, CD-Venture, and Baird Capital.